Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

551

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Hypertension
Interventions
DRUG

Azilsartan medoxomil and chlorthalidone

Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.

DRUG

Azilsartan medoxomil and chlorthalidone

Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.

DRUG

Chlorthalidone

Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.

Trial Locations (46)

Unknown

Huntsville

Montgomery

Buena Park

Huntington Beach

Long Beach

Mission Viejo

Roseville

Sacramento

Westlake Village

Coral Gables

DeLand

Fort Lauderdale

Hollywood

Miami

Auburn

Bingham Farms

Troy

Charlotte

Huntersville

Shelby

Akron

Centerville

Cincinnati

Willoughby Hills

Zanesville

Norman

Oklahoma City

Eugene

Portland

Tualatin

Bensalem

Feasterville

Cranston

Simpsonville

Kingsport

Corpus Christi

Houston

Pearland

San Antonio

Salt Lake City

Arlington

Burke

Richmond

Lakewood

Olympia

Port Orchard

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY